Archives

ICON Announces Appointment of Barry Balfe as COO.

ICON

ICON plc, a world-leading healthcare intelligence and clinical research organisation, announced the appointment of Barry Balfe as Chief Operating Officer (COO).

Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to become the healthcare intelligence partner of choice in the industry.

Barry will continue to report to ICON’s Chief Executive Officer, Steve Cutler.

Also Read: Gilead and Terray Launch Collaboration for Small Molecule Therapies

“Barry is a vastly experienced leader and has a very strong reputation across the industry,” said Steve Cutler, ICON’s CEO. “He has successfully led our largest division over the past number of years, creating and sustaining strategic partnerships with customers that have been key to our growth trajectory as a company. I look forward to working closely with Barry to drive further growth across the organisation, as we create value for our customers in delivering their clinical development programs more efficiently.”

“It is a privilege to serve as ICON’s Chief Operating Officer,” said Barry Balfe. “I look forward to working with all of our dedicated colleagues around the world as we continue to drive superior innovation, execution and delivery for customers and for patients.”

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives.

SOURCE: Businesswire